Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bevacizumab + Cisplatin + GL-ONC1|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 10 VEGFR Inhibitor (Pan) 33||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Cisplatin||Platinol||CDDP||Chemotherapy - Platinum 7||Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).|
|GL-ONC1||GLV-1h68|Olvimulogene nanivacirepvec|Olvi-Vec||Olvimulogene nanivacirepvec (GL-ONC1) is a genetically engineered light-emitting oncolytic vaccinia virus, which results in viral infection within the cells, thereby possibly inducing cell death and interruption of the cell cycle (PMID: 28679776, PMID: 31567308).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05281471||Phase III||Bevacizumab + Carboplatin Bevacizumab + Cisplatin Bevacizumab + Carboplatin + GL-ONC1 Bevacizumab + Cisplatin + GL-ONC1||Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime)||Recruiting||USA||0|